Search research articles
Contact Us
Filters
Showing results (1-10 of 574) with videos related to
Page
of 58
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
December 19, 2017
The era of GWAS is over - No
Philip L De Jager
Neurobiology of Disease
|
March 12, 2021
Deconstructing the epigenomic architecture of human neurodegeneration
Philip L De Jager
Therapeutic Advances in Neurological Disorders
|
December 25, 2010
Identifying patient subtypes in multiple sclerosis and tailoring immunotherapy: challenges for the future
Philip L De Jager
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
June 12, 2018
Is the goal of an epigenomic study to determine causality?
Philip L De Jager
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
April 26, 2018
Designing an epigenomic study
Yiyi Ma, Philip L De Jager
Molecular Psychiatry
|
June 6, 2022
Neuroimmune contributions to Alzheimer's disease: a focus on human data
Verena Haage, Philip L De Jager
Continuum (Minneapolis, Minn.)
|
July 20, 2012
Uncovering the genetic architecture of multiple sclerosis
Federica Esposito, Philip L De Jager
Journal of Neuroimmunology
|
February 3, 2012
Exploring the role of the epigenome in multiple sclerosis: a window onto cell-specific transcriptional potential
Anna Kaliszewska, Philip L De Jager
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
May 24, 2018
Evaluating the role of genetic variation in the epigenome in health and disease
Tina Roostaei, Philip L De Jager
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
March 3, 2018
What is the epigenome and is it involved in multiple sclerosis?
Ji Y Lee, Philip L De Jager
Page
of 58
Search research articles
Search
Showing results (1-10 of 574) with videos related to
Sort By:
Page
of 58
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
December 19, 2017
The era of GWAS is over - No
Philip L De Jager
Neurobiology of Disease
|
March 12, 2021
Deconstructing the epigenomic architecture of human neurodegeneration
Philip L De Jager
Therapeutic Advances in Neurological Disorders
|
December 25, 2010
Identifying patient subtypes in multiple sclerosis and tailoring immunotherapy: challenges for the future
Philip L De Jager
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
June 12, 2018
Is the goal of an epigenomic study to determine causality?
Philip L De Jager
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
April 26, 2018
Designing an epigenomic study
Yiyi Ma, Philip L De Jager
Molecular Psychiatry
|
June 6, 2022
Neuroimmune contributions to Alzheimer's disease: a focus on human data
Verena Haage, Philip L De Jager
Continuum (Minneapolis, Minn.)
|
July 20, 2012
Uncovering the genetic architecture of multiple sclerosis
Federica Esposito, Philip L De Jager
Journal of Neuroimmunology
|
February 3, 2012
Exploring the role of the epigenome in multiple sclerosis: a window onto cell-specific transcriptional potential
Anna Kaliszewska, Philip L De Jager
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
May 24, 2018
Evaluating the role of genetic variation in the epigenome in health and disease
Tina Roostaei, Philip L De Jager
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
March 3, 2018
What is the epigenome and is it involved in multiple sclerosis?
Ji Y Lee, Philip L De Jager
Page
of 58